Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4259505 | Transplantation Proceedings | 2009 | 4 Pages |
Abstract
Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
S. Schneeberger, L. Landin, C. Kaufmann, V.S. Gorantla, G. Brandacher, P. Cavadas, W.P.A. Lee, W.C. Breidenbach, R. Margreiter,